Ibrutinib-Induced Vasculitis in a Patient with Metastatic Colon Cancer Treated in Combination with Cetuximab

Combination therapy with ibrutinib and cetuximab is being studied in a phase 1b/2 trial in patients with advanced gastrointestinal and genitourinary malignancies. Rash is a common cutaneous adverse effect for both medications. Ibrutinib is a Bruton's tyrosine kinase (BTK) inhibitor approved for...

Descripción completa

Detalles Bibliográficos
Autores principales: Chi, Jeffrey, Park, Jennifer, Saif, Muhammad Wasif
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7042512/
https://www.ncbi.nlm.nih.gov/pubmed/32110454
http://dx.doi.org/10.1155/2020/6154213

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7042512/
https://www.ncbi.nlm.nih.gov/pubmed/32110454
http://dx.doi.org/10.1155/2020/6154213

Ejemplares similares